Seres Therapeutics, Inc.
$1.5M 42 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. reported $1,455,875.46 across General Payments, Research, and Ownership to 21,104 physicians and teaching hospitals across 21,112 transactions.
- $1.5M Above-median payer
- All-tracks total
- 21,112 Top 10% volume
- Transactions
- 21,104 Top 10% reach
- Recipients
- +$277.1K
- General Payments vs PY2023
ANI Pharmaceuticals, Inc. reported $1,455,875.46 across all CMS Open Payments tracks (General + Research + Ownership) to 21,104 physicians and teaching hospitals in Program Year 2024 - ranking #533 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,125,992.16, averaging $68.99 per recipient.
How ANI Pharmaceuticals, Inc.'s $1.5M all-tracks total breaks down
ANI Pharmaceuticals, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
C
72/100
Total payments
F
23/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer ani-pharmaceuticals-inc ANI Pharmaceuticals, Inc.
$1.5M · #533/1,925 · 0.0% industry · PY2024
- TOT $1.5M
- RANK #533
- SHARE 0.0%
- TXN 21,112
- RCP 21,104
- CAT 5
- GEN $1.1M
- ΔGEN +$277.1K
- TOP1 6.1%
- PY 2024
Volume peers
Nearest volume peer: Seres Therapeutics, Inc. ($1.5M)
ANI Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
ANI Pharmaceuticals, Inc.'s CMS-reported General Payments increased by $277.1K (+32.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ANI PHARMACEUTICALS, INC.PY2023: ANI PHARMACEUTICALS, INC.PY2024: ANI Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $848,894.93
- PY2024
- $1,125,992.16
What the Data Shows for ANI Pharmaceuticals, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For ANI Pharmaceuticals, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
The 5-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $556.7K, accounting for 49.4% of this company's General Payments and 20,504 transactions.
General Payment Breakdown by Type
"Food and Beverage" leads ANI Pharmaceuticals, Inc.'s 5-category general-payment breakdown at $556.7K, 49.4% of the reported total.
ANI Pharmaceuticals, Inc. reports 5 general-payment categories - the top three are Food and Beverage (49.4%), Honoraria (38.8%), and Travel and Lodging (10.4%). The remaining 2 categories make up 1.3% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How ANI Pharmaceuticals, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $556.7K | 20,504 | 49.4% |
| Honoraria | $437.2K | 199 | 38.8% |
| Travel and Lodging | $117.4K | 391 | 10.4% |
| Space Rental or Facility Fees | $14.8K | 6 | 1.3% |
| Education | $30.02 | 4 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $179,388.48 (15.9%) of $1,125,992.16 in this company's General Payments records across 7,212 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for ANI Pharmaceuticals, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Sudhakar Tumuluri
$68,997.79 across 110 reported transactions
- 2
Dhiman Basu
$40,112.74 across 70 reported transactions
- 3
Regina Berkovich
$25,256.95 across 51 reported transactions
- 4
Payam Shakouri
$24,637.75 across 44 reported transactions
- 5
Petros Efthimiou
$20,383.25 across 26 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
ANI Pharmaceuticals, Inc. ranks #533 of 1,925 by total payments (top 28% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,693 of 1,838 by HHI (bottom 8% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Neurelis, Inc. : $1.9M total payments, HHI 104
- ACADIA Pharmaceuticals Inc : $2.6M total payments, HHI 102
- Biotronik Inc. : $2.4M total payments, HHI 102
- CSL Plasma Inc. : $17.9M total payments, HHI 100
- Ardelyx, Inc. : $1.8M total payments, HHI 99
- Synthes GmbH : $2.5M total payments, HHI 99
- ANI Pharmaceuticals, Inc. (this company) : $1.1M total payments, HHI 98
- Arcutis Biotherapeutics, Inc. : $5.0M total payments, HHI 97
- CVRx, Inc. : $1.5M total payments, HHI 97
- Peerless Surgical Inc. : $139.0K total payments, HHI 96
- Gemini Mountain Medical, LLC : $85.4K total payments, HHI 96
- InSightec,Inc : $120.8K total payments, HHI 96
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as ANI Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about ANI Pharmaceuticals, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with ANI Pharmaceuticals, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Rti Surgical, Inc
$1.4M 821 recipients
Compare payment profiles
FUJIFILM Healthcare Americas Corporation
$1.5M 993 recipients
Compare payment profiles
Esteve Pharmaceuticals LLC
$1.4M 8 recipients
Compare payment profiles
Servier Pharmaceuticals LLC
$1.5M 5,634 recipients
Compare payment profiles
Adaptive Biotechnologies Corporation
$1.5M 3,663 recipients
Compare payment profiles
Put this to use
ANI Pharmaceuticals, Inc. ranks #533 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See where ANI Pharmaceuticals, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just ANI Pharmaceuticals, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.